Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Apr 18;10(4):646-651.
doi: 10.18240/ijo.2017.04.23. eCollection 2017.

Applications of CRISPR/Cas9 in retinal degenerative diseases

Ying-Qian Peng  1 , Luo-Sheng Tang  1 , Shigeo Yoshida  2 , Ye-Di Zhou  1
Affiliations
Review

Applications of CRISPR/Cas9 in retinal degenerative diseases

Ying-Qian Peng et al. Int J Ophthalmol. .

Abstract

Gene therapy is a potentially effective treatment for retinal degenerative diseases. Clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) system has been developed as a new genome-editing tool in ophthalmic studies. Recent advances in researches showed that CRISPR/Cas9 has been applied in generating animal models as well as gene therapy in vivo of retinitis pigmentosa (RP) and leber congenital amaurosis (LCA). It has also been shown as a potential attempt for clinic by combining with other technologies such as adeno-associated virus (AAV) and induced pluripotent stem cells (iPSCs). In this review, we highlight the main points of further prospect of using CRISPR/Cas9 in targeting retinal degeneration. We also emphasize the potential applications of this technique in treating retinal degenerative diseases.

Keywords: CRISPR/Cas9; gene therapy; genome editing; leber congenital amaurosis; retinal degeneration; retinitis pigmentosa.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Structure and applications of CRISPR/Cas9 in retinal degenerative diseases
BH: Bridge helix; PI: PAM interacting. The structure of Cas9 protein of this figure is adapted from Cavanagh&Garrity, “CRISPR Mechanism”, CRISPR/Cas9, Tufts University, 2014. Available at https://sites.tufts.edu/crispr/; accessed on Dec. 23, 2016.
See this image and copyright information in PMC

References

    1. Sundaramurthy S, Swaminathan M, Sen P, Arokiasamy T, Deshpande S, John N, Gadkari RA, Mannan AU, Soumittra N. Homozygosity mapping guided next generation sequencing to identify the causative genetic variation in inherited retinal degenerative diseases. J Hum Genet. 2016;61(11):951–958. - PubMed
    1. Jones BW, Pfeiffer RL, Ferrell WD, Watt CB, Marmor M, Marc RE. Retinal remodeling in human retinitis pigmentosa. Exp Eye Res. 2016;150:149–165. - PMC - PubMed
    1. Nowak JZ. AMD-the retinal disease with an unprecised etiopathogenesis: in search of effective therapeutics. Acta Pol Pharm. 2014;71(6):900–916. - PubMed
    1. Scholl HP, Strauss RW, Singh MS, Dalkara D, Roska B, Picaud S, Sahel JA. Emerging therapies for inherited retinal degeneration. Sci Transl Med. 2016;8(368):368rv6. - PubMed
    1. Dalkara D, Goureau O, Marazova K, Sahel JA. Let There Be Light: Gene and Cell Therapy for Blindness. Hum Gene Ther. 2016;27(2):134–147. - PMC - PubMed

LinkOut - more resources